Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
Worth Seeing!
Top Stocks to Buy: Get 13 Picks That We Think Will Soar
Claim Your Stock Picks
Claim Your Stock Picks
BSE: 524400 | NSE: | Pharmaceuticals & Drugs | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Ishita Drugs & Industries Ltd is a average quality company.
The key valuation ratios of Ishita Drugs & Industries Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Ishita Drugs & Industries Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 5.8% | 4.4% | 3.1% | 3.4% | 4.6% | 5.1% | 7.1% | 8.8% | 9.7% | 6.1% | - |
| Value Creation Index ⓘ | -0.6 | -0.7 | -0.8 | -0.8 | -0.7 | -0.6 | -0.5 | -0.4 | -0.3 | -0.6 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 6.7 | 7 | 6.5 | 5.8 | 6.8 | 9.1 | 14.8 | 14 | 14.1 | 12.1 | 13 |
| Sales YoY Gr. | - | 3.4% | -6.2% | -10.7% | 15.9% | 34.3% | 63.2% | -5.9% | 1% | -14.3% | - |
| Adj EPS ⓘ | 1 | 0.7 | 0.5 | 0.6 | 0.7 | 1 | 1.6 | 2.1 | 2.6 | 1.8 | 2.2 |
| YoY Gr. | - | -26% | -29.6% | 22% | 6.6% | 47.7% | 62.5% | 37.2% | 21.5% | -30.8% | - |
| BVPS (₹) ⓘ | 17.6 | 18.4 | 18.8 | 19.4 | 20.3 | 21.5 | 23.3 | 26.1 | 28.8 | 30.7 | 32.2 |
| Adj Net Profit ⓘ | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.3 | 0.5 | 0.6 | 0.8 | 0.5 | 1 |
| Cash Flow from Ops. ⓘ | 0.7 | 0.1 | 0.3 | 0.5 | 0.7 | 0.8 | 1.1 | -0.7 | 3.1 | -2.9 | - |
| Debt/CF from Ops. ⓘ | 0.3 | 0.8 | 4.3 | 0 | 0.2 | 0.3 | 0.3 | -0.1 | 0 | -0.3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 6.7% | 12.3% | -6.6% | -14.3% | ||||
| Adj EPS ⓘ | 7.2% | 22.6% | 4.9% | -30.8% | ||||
| BVPSⓘ | 6.4% | 8.6% | 9.6% | 6.7% | ||||
| Share Price | 16.8% | 31.7% | 29.4% | 39.5% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 5.6 | 4 | 2.7 | 3.2 | 3.3 | 4.6 | 7 | 8.7 | 9.5 | 6.1 | 6.9 |
| Op. Profit Mgn % ⓘ | 6.7 | 4.5 | 4.1 | 5.5 | 6.7 | 5.7 | 5.2 | 6.6 | 7.7 | 6.3 | 6.4 |
| Net Profit Mgn % ⓘ | 4.3 | 3.1 | 2.3 | 3.1 | 2.9 | 3.1 | 3.1 | 4.6 | 5.5 | 4.5 | 4.9 |
| Debt to Equity ⓘ | 0 | 0 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | - |
| Working Cap Days ⓘ | 169 | 124 | 141 | 145 | 105 | 72 | 50 | 62 | 55 | 80 | 148 |
| Cash Conv. Cycle ⓘ | 52 | 54 | 64 | 56 | 49 | 27 | 3 | 11 | 3 | 25 | 111 |
No data to display
Return on Equity has declined versus last 3 years average to 6.90%
Sales growth has been subdued in last 3 years -6.63%
Net Profit has been subdued in last 3 years 4.89%
Sales growth is not so good in last 4 quarters at 2.89%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 2.2 | - |
| TTM Sales (₹ Cr.) | 13.3 | - |
| BVPS (₹.) ⓘ | 32.2 | - |
| Reserves (₹ Cr.) ⓘ | 7 | - |
| P/BV ⓘ | 2.20 | - |
| PE ⓘ | 32.82 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 46.01 / 98.37 |
| All Time Low / High (₹) | 0.10 / 98.37 |
| Market Cap (₹ Cr.) | 21.2 |
| Equity (₹ Cr.) | 3 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 47.6 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6.74 | 6.97 | 6.54 | 5.84 | 6.77 | 9.09 | 14.83 | 13.95 | 14.09 | 12.07 |
| Operating Expenses ⓘ | 6.41 | 6.66 | 6.29 | 5.55 | 6.32 | 8.57 | 14.07 | 13.03 | 13 | 11.31 |
| Manufacturing Costs | 0.40 | 0.37 | 0.27 | 0.42 | 0.41 | 0.68 | 0.77 | 0.72 | 0.63 | 0.51 |
| Material Costs | 4.82 | 5.19 | 5.02 | 3.95 | 4.71 | 6.37 | 11.41 | 10.23 | 10.14 | 8.51 |
| Employee Cost | 0.37 | 0.42 | 0.41 | 0.45 | 0.56 | 0.67 | 0.76 | 0.76 | 0.76 | 0.77 |
| Other Costs ⓘ | 0.82 | 0.67 | 0.59 | 0.73 | 0.64 | 0.86 | 1.12 | 1.32 | 1.47 | 1.51 |
| Operating Profit ⓘ | 0.33 | 0.31 | 0.25 | 0.29 | 0.45 | 0.52 | 0.76 | 0.92 | 1.09 | 0.76 |
| Operating Profit Margin (%) | 4.9% | 4.4% | 3.8% | 4.9% | 6.7% | 5.7% | 5.1% | 6.6% | 7.7% | 6.3% |
| Other Income ⓘ | 0.12 | 0.17 | 0.15 | 0.15 | 0.12 | 0.16 | 0.16 | 0.31 | 0.11 | 0.20 |
| Interest ⓘ | 0.03 | 0.04 | 0.06 | 0.04 | 0.11 | 0.06 | 0.03 | 0.03 | 0.02 | 0.05 |
| Depreciation ⓘ | 0.12 | 0.15 | 0.15 | 0.14 | 0.14 | 0.16 | 0.18 | 0.15 | 0.13 | 0.13 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 0.30 | 0.29 | 0.19 | 0.26 | 0.32 | 0.46 | 0.71 | 1.05 | 1.04 | 0.78 |
| Tax ⓘ | 0.10 | 0.07 | 0.06 | 0.07 | 0.08 | 0.11 | 0.17 | 0.22 | 0.24 | 0.20 |
| Profit After Tax | 0.20 | 0.22 | 0.14 | 0.18 | 0.25 | 0.35 | 0.55 | 0.83 | 0.80 | 0.58 |
| PAT Margin (%) | 3.0% | 3.2% | 2.1% | 3.1% | 3.7% | 3.9% | 3.7% | 5.9% | 5.7% | 4.8% |
| Adjusted EPS (₹) | 0.7 | 0.7 | 0.5 | 0.6 | 0.8 | 1.2 | 1.8 | 2.8 | 2.7 | 1.9 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 5.27 | 5.49 | 5.63 | 5.81 | 6.06 | 6.41 | 6.96 | 7.79 | 8.60 | 9.17 |
| Share Capital ⓘ | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 |
| Reserves ⓘ | 2.28 | 2.50 | 2.64 | 2.82 | 3.07 | 3.42 | 3.97 | 4.80 | 5.61 | 6.18 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 0.09 | 0.02 | 1.11 | 0.01 | 0.09 | 0.13 | 0.21 | 0 | 0 | 0.96 |
| Long Term Debt | 0.09 | 0.02 | 0 | 0 | 0.08 | 0.12 | 0.04 | 0 | 0 | 0 |
| Short Term Debt | 0 | 0 | 1.11 | 0.01 | 0 | 0 | 0.17 | 0 | 0 | 0.96 |
| Trade Payables | 0.92 | 1.12 | 1.26 | 1.18 | 0.56 | 1.38 | 1.89 | 0.98 | 2.04 | 0.86 |
| Others Liabilities ⓘ | 0.32 | 0.33 | 0.21 | 0.18 | 0.44 | 0.42 | 0.48 | 0.49 | 0.62 | 0.42 |
| Total Liabilities ⓘ | 6.61 | 6.97 | 8.20 | 7.19 | 7.15 | 8.34 | 9.55 | 9.26 | 11.25 | 11.41 |
Fixed Assets | ||||||||||
| Gross Block | 4.05 | 4.11 | 4.11 | 4.16 | 4.46 | 4.73 | 4.75 | 4.75 | 4.60 | 4.73 |
| Accumulated Depreciation | 2.69 | 2.85 | 3 | 3.14 | 3.28 | 3.43 | 3.61 | 3.76 | 3.71 | 3.84 |
| Net Fixed Assetsⓘ | 1.36 | 1.26 | 1.11 | 1.02 | 1.19 | 1.30 | 1.14 | 1 | 0.88 | 0.89 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 1.45 | 1.82 | 2.15 | 2.70 | 3.15 | 4.04 | 5.29 | 3.11 | 4.06 | 3.39 |
| Inventories | 0.97 | 1.31 | 0.77 | 0.56 | 0.72 | 0.74 | 0.58 | 0.65 | 0.97 | 1.60 |
| Trade Receivables | 1.05 | 1.25 | 1.88 | 1.70 | 0.82 | 1.18 | 1.31 | 1.52 | 0.54 | 1.80 |
Cash Equivalents  ⓘ
| 1.44 | 1.14 | 2.19 | 1.11 | 1.20 | 1.01 | 1 | 2.54 | 4.68 | 3.43 |
| Others Assetsⓘ | 0.35 | 0.19 | 0.09 | 0.10 | 0.08 | 0.07 | 0.22 | 0.44 | 0.11 | 0.30 |
| Total Assets ⓘ | 6.61 | 6.97 | 8.20 | 7.19 | 7.15 | 8.34 | 9.55 | 9.26 | 11.25 | 11.41 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 0.74 | 0.11 | 0.26 | 0.52 | 0.72 | 0.79 | 1.05 | -0.67 | 3.08 | -2.90 |
| PBT ⓘ | 0.30 | 0.29 | 0.19 | 0.26 | 0.32 | 0.46 | 0.71 | 1.05 | 1.04 | 0.78 |
| Adjustment ⓘ | 0.03 | 0.04 | 0.06 | 0.03 | 0.13 | 0.05 | 0.05 | -0.14 | 0.05 | -0.02 |
| Changes in Working Capital ⓘ | 0.5 | -0.15 | 0.08 | 0.32 | 0.35 | 0.39 | 0.46 | -1.36 | 2.24 | -3.45 |
| Tax Paid ⓘ | -0.11 | -0.10 | -0.07 | -0.09 | -0.08 | -0.12 | -0.18 | -0.23 | -0.25 | -0.21 |
| Cash Flow From Investing Activity ⓘ | -0.45 | -0.34 | -0.28 | -0.55 | -0.69 | -1.06 | -1.15 | 2.45 | -0.93 | 0.59 |
| Capex | -0.30 | -0.05 | -0.01 | -0.04 | -0.31 | 0 | 0 | 0 | 0 | 0 |
| Net Investments | -0.24 | -0.37 | -0.33 | -0.51 | -0.38 | -1.06 | -1.27 | 2.18 | -0.97 | 0.54 |
| Others ⓘ | 0.08 | 0.09 | 0.06 | 0 | 0 | 0 | 0.12 | 0.27 | 0.04 | 0.06 |
| Cash Flow From Financing Activityⓘ | 0.03 | -0.07 | 1.07 | -1.05 | 0.05 | 0.09 | 0.09 | -0.24 | 0 | 1.05 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | -0.03 | -0.04 | -0.06 | -0.04 | -0.11 | -0.06 | -0.03 | -0.03 | -0.02 | -0.05 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 0.06 | -0.03 | 1.13 | -1 | 0.16 | 0.15 | 0.13 | -0.21 | 0.03 | 1.10 |
| Net Cash Flow ⓘ | 0.32 | -0.29 | 1.05 | -1.08 | 0.08 | -0.19 | -0.01 | 1.54 | 2.14 | -1.25 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 3.95 | 4.12 | 2.47 | 3.19 | 4.17 | 5.64 | 8.18 | 11.25 | 9.82 | 6.5 |
| ROCE (%) | 6.27 | 5.98 | 4.02 | 4.79 | 7.26 | 8.17 | 10.79 | 14.39 | 13 | 8.9 |
| Asset Turnover Ratio | 1.01 | 1.11 | 0.94 | 0.84 | 0.96 | 1.17 | 1.66 | 1.48 | 1.37 | 1.07 |
| PAT to CFO Conversion(x) | 3.7 | 0.5 | 1.86 | 2.89 | 2.88 | 2.26 | 1.91 | -0.81 | 3.85 | -5 | Working Capital Days |
| Receivable Days | 97 | 56 | 81 | 102 | 67 | 40 | 31 | 37 | 27 | 35 |
| Inventory Days | 56 | 55 | 53 | 38 | 34 | 29 | 16 | 16 | 21 | 39 |
| Payable Days | 128 | 72 | 86 | 113 | 68 | 56 | 52 | 51 | 54 | 62 |
Ishita drugs & industries limited (IDIL), an Ishita Group company was incorporated in 1992, the company is listed on the local stock exchanges in India and has earned a reputation as a 'high quality manufacturer' in a very short time.
IDIL is engaged in the manufacture of various active pharma ingredients (bulk actives and their salts), bulk drug intermediates, excipients and fine chemicals. It has a state-of-art manufacturing facility, in terms of chemical synthesis, quality control and environmental safety.
Ishita Group is a respected member of the Indian business community for more than 3 decades. The group's interests encompass manufacture of a large number of bulk actives and their salts, drug intermediates, fine chemicals, food additives, specialty/ performance chemicals, pharmaceutical formulations, healthcare products, dyes and dye intermediates, distribution of financial products and other businesses. The ishita group derives its key strengths from its strong ethical practices and moral values in business commitments.
The company’s manufacturing facility is located on main State Highway 17, barely 25 km from Ahmedabad city. The plant incorporates facilities that are the state-of-art in chemical synthesis, quality control and energy efficiency. The provision of several different utility systems and equipments covering a large number of unit operations make the plant truly multi-purpose. This imparts the flexibility to alter the product mix in tune with the changing market needs or the needs of the customers for customized products.
The plant is equipped with various kinds of equipment to carry out varied kinds of reactions - ss vessels, glass lined ss reactors (glrs), ss centrifuges, rubber lined centrifuges, condensers, fluid bed dryers, ribbon blender, commuting mill, leaf filters, vibrator separators, multi mill etc. The plant also have various utilities suitable for different processes - oil heating, steam heating, ammonia chilling, brine chilling, compressed air, vacuum systems etc.
Product range of the company includes:
The current product list of Ishita includes APIs and intermediates
APIs
AntibioticsChloramphenicol bp/usp
Fluoro quinolones
Sulpha drugs
Vitamins
Anthelmintics
Iodides & citrates (salts)
Excipients
Other chemicals
Intermediaries
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
